Skip to content
Med Rx.

Dipyridamole interactions

Full monograph for DipyridamoleCheck it against another medicine

Medicines

368 documented

Medicines documented to interact with Dipyridamole, worst severity first.
MedicineSeverityMechanismEffectSources
AcalabrutinibMajorSynergyCoadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.3 sources — open the full entry
ApixabanMajorSynergyConcomitant use of apixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation…39 sources — open the full entry
BetrixabanMajorSynergyConcomitant use of betrixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation…39 sources — open the full entry
CabozantinibMajorSynergyCoadministration of cabozantinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment…39 sources — open the full entry
Dabigatran Etexilate MesylateMajorSynergyCoadministration of thrombin inhibitors with drugs that affect platelet function may potentiate the risk of bleeding due to additive or synergistic effects on…2 sources — open the full entry
Dalteparin SodiumMajorSynergyDrugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the…7 sources — open the full entry
DasatinibMajorSynergyCoadministration of dasatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with…5 sources — open the full entry
DeferasiroxMajorSynergyCoadministration with drugs that have known ulcerogenic or hemorrhagic potential may increase the risk of gastrointestinal bleeding associated with the use of…3 sources — open the full entry
Enoxaparin SodiumMajorSynergyDrugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the…7 sources — open the full entry
EptifibatideMajorSynergyThe combination of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors and other drugs that inhibit platelet aggregation may significantly increase the risk of…5 sources — open the full entry
Fondaparinux SodiumMajorSynergyDrugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the…7 sources — open the full entry
IbrutinibMajorSynergyCoadministration of ibrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.6 sources — open the full entry
Ponatinib HydrochlorideMajorSynergyCoadministration of ponatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with…3 sources — open the full entry
Prasugrel HydrochlorideMajorSynergyConcomitant use of prasugrel with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents…2 sources — open the full entry
RamucirumabMajorSynergyCoadministration of ramucirumab and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Ramucirumab…2 sources — open the full entry
Regorafenib MonohydrateMajorSynergyCoadministration of regorafenib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment…5 sources — open the full entry
RivaroxabanMajorSynergyConcomitant use of rivaroxaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation…1 sources — open the full entry
Tirofiban HydrochlorideMajorSynergyThe combination of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors and other drugs that inhibit platelet aggregation may significantly increase the risk of…5 sources — open the full entry
Trastuzumab EmtansineMajorSynergyCoadministration of trastuzumab emtansine with anticoagulant or antiplatelet drugs may potentiate the risk of hemorrhagic events associated with these drugs…40 sources — open the full entry
AdenosineModerateSynergyDipyridamole potentiates the effects of adenosine. The mechanism probably is inhibition of endogenous and exogenous adenosine reuptake, which increases plasma…16 sources — open the full entry
Adenosine + Cytochrome-C + Sodium Succinate + NicotinamideModerateSynergyDipyridamole potentiates the effects of adenosine. The mechanism probably is inhibition of endogenous and exogenous adenosine reuptake, which increases plasma…16 sources — open the full entry
AlteplaseModerateSynergyDrugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.8 sources — open the full entry
AminophyllineModerateAntagonismINTERVAL: Methylxanthines (e.g., caffeine, theophylline) are nonspecific, competitive antagonists of adenosine receptors. As such, they may interfere with the…10 sources — open the full entry
Beta carotene + Vitamin C + Vitamin EModerateSynergyVitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and…20 sources — open the full entry
BivalirudinModerateSynergyThe safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the…1 sources — open the full entry
Bromfenac SodiumModerateSynergySystemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with…3 sources — open the full entry
Caffeine CitrateModerateAntagonismINTERVAL: Methylxanthines (e.g., caffeine, theophylline) are nonspecific, competitive antagonists of adenosine receptors. As such, they may interfere with the…10 sources — open the full entry
CilostazolModerateSynergyCoadministration of cilostazol with other antiplatelet agents may produce additive pharmacodynamic effects resulting in increased inhibition of platelet…4 sources — open the full entry
Citalopram HydrobromideModerateSynergySerotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as…42 sources — open the full entry
Clomipramine HydrochlorideModerateSynergySerotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as…42 sources — open the full entry
Desvenlafaxine SuccinateModerateSynergySerotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as…42 sources — open the full entry
DexibuprofenModerateSynergySystemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with…3 sources — open the full entry
DexketoprofenModerateSynergySystemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with…3 sources — open the full entry
Diclofenac Diethylamine + Mephenesin + Menthol + Methyl Salicylate + Turpentine OilModerateSynergySystemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with…3 sources — open the full entry
Diclofenac PotassiumModerateSynergySystemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with…3 sources — open the full entry
Diclofenac SodiumModerateSynergySystemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with…3 sources — open the full entry
Diclofenac Sodium (Ophthalmic)ModerateSynergySystemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with…3 sources — open the full entry
Diclofenac Sodium + Lidocaine HydrochlorideModerateSynergySystemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with…3 sources — open the full entry
Diclofenac Sodium + Methyl Salicylate + Linseed Oil + MentholModerateSynergySystemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with…3 sources — open the full entry
Diclofenac Sodium + MisoprostolModerateSynergySystemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with…3 sources — open the full entry
Duloxetine HydrochlorideModerateSynergySerotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as…42 sources — open the full entry
Escitalopram OxalateModerateSynergySerotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as…42 sources — open the full entry
EtodolacModerateSynergySystemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with…3 sources — open the full entry
Fludarabine PhosphateModerateAbsorptionThe concomitant administration of dipyridamole may theoretically reduce the therapeutic efficacy of fludarabine. Dipyridamole is an adenosine uptake inhibitor…5 sources — open the full entry
Fluoxetine HydrochlorideModerateSynergySerotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as…42 sources — open the full entry
FlurbiprofenModerateSynergySystemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with…3 sources — open the full entry
Fluvoxamine MaleateModerateSynergySerotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as…42 sources — open the full entry
IbuprofenOralTopicalModerateSynergySystemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with…3 sources — open the full entry
Ibuprofen + ParacetamolModerateSynergy · UnknownSystemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with…2 documented mechanisms3 sources — open the full entry
Icosapent EthylModerateSynergyOmega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet…7 sources — open the full entry

Food & lifestyle

Conditions

Conditions in which Dipyridamole needs care, as documented in this source.